Bioventix carries a reputation as a quietly premium lab reagent business with rich profitability and a chunky dividend, yet the latest full year 2026 figures tell a more nuanced story than the share price suggests. The stock closed at £19.90 on 27 October after a strong recent run, while earnings over the past year barely moved, with profits growing only 0.4%.
The real hook is not the income statement. Net profit margin over the last 12 months sat at an eye catching 58.7%, so the market reaction is bumping up against a business already operating at elite profitability.
Love Bioventix's rich 58.7% net profit margin but concerned that earnings barely moved with just 0.4% profit growth? Compare it with other highly profitable lab and healthcare stocks in our list of solid balance sheet and fundamentals stocks (10 results)
FY 2026 Earnings Summary
- Revenue (FY 2026 vs FY 2025 TTM): £12.97m vs. £13.12m (relatively flat top line, slightly lower than the prior year trailing twelve months)
- Net Income (FY 2026 vs FY 2025 TTM): £7.61m vs. £7.58m (0.4% increase in trailing twelve month earnings)
- Basic EPS (FY 2026 vs FY 2025 TTM): £1.46 per share vs. £1.45 per share (marginal uplift in per share profitability)
- Net Profit Margin (FY 2026 TTM vs FY 2025 TTM): 58.7% vs. 57.8% (already high profitability edged higher year on year)
Bioventix posts rich margins but trades at a discount. Ask Charlie what makes Bioventix look so undervalued.
Bioventix bull case leans on resilient economics
For anyone leaning positive on Bioventix, the appeal rests on resilience rather than excitement. Revenue of £12.97m is close to the prior period, yet net profit still reached £7.61m and margin held at 58.7%. That combination points to a business model that protects profitability even when top line progress is muted. Recent share price strength over 30 and 90 days also signals that investors are rewarding this income profile, not chasing rapid expansion.
Muted growth keeps Bioventix bear arguments alive
On the flip side, the latest figures give fuel to those who worry about limited momentum. Revenue is slightly lower than the prior twelve month period, while net income has barely shifted with a 0.4% uplift and only a 1p move in basic EPS to £1.46. Profitability remains high, which softens near term risk to the balance sheet, yet the combination of flat earnings and a strong share price run invites questions about how much fundamental progress is really being made today.
After a share price push to £19.90 with only 0.4% profit growth and a rich dividend, it is worth asking whether Bioventix is quietly stretching its payout or taking on other less obvious pressures that do not show up in one set of annual figures. Scan the independent risk analysis for Bioventix which shows 1 important warning signHunt For Quiet Mispricings
Bioventix pairs sturdy margins with muted progress, so the recent share price move may overstate any shift in fundamentals. The real opportunity could sit in stocks where fundamentals and valuation quietly drift apart.
- Company 1 - 25% below our estimate - uses new growth projects to ramp copper concentrate output as supply contracts tighten.
- Company 2 - 34% below our estimate - pushes a membership model and recommerce platform to deepen customer spend and lower service costs.
- Company 3 - 30% below our estimate - folds a specialist IT reseller into its platform to extend into AI-focused infrastructure projects.
Three companies from the same screener. Open every one of the 10 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com